Treatment of Metastatic Breast Cancer: A Multiplication of Options

Avan J. Armaghani, MD


August 01, 2022

Avan J. Armaghani, MD, considers the evolution in therapies for metastatic breast cancer (mBC), from the bygone era of chemotherapy as the primary recourse to the enhanced contemporary scene, for which immunotherapy has opened new possibilities in strategic treatment.

Agents such as trastuzumab and pembrolizumab offer patients with mBC a range of second-line options that bring with them not just prospects of more immediate improvements in terms of safety and efficacy but also the anticipation of long-term benefits in the form of extended rates of survival.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.